^
    Back
    Association details:
    Biomarker:PTEN mutation
    Cancer:Triple Negative Breast Cancer
    Drug:everolimus (mTOR inhibitor) +
    SNX-631 (CDK8/19 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    SABCS 2022
    Title:

    PD5-10 Dual therapeutic targeting of CDK8/19 and mTOR in triple negative breast cancer

    Published date:
    11/22/2022
    Excerpt:
    We also analyzed the effect of CDK8/19 inhibition on the outcome of treatment with mTORC1 inhibitor everolimus (RAD001), an approved drug for several cancers with mutations of PTEN or PI3KCA. SNX631 exhibited a synergistic effect in combination with everolimus on suppressing TNBC cell growth in vitro.